Urvi Shah: Jasmin Hundal and I summarize the results of the DIANA-5 trial
Urvi Shah, Oncologist and Researcher on Myeloma Service at the Memorial Sloan Kettering Cancer Centre, shared a post on X/Twitter:
“Jasmin Hundal and I summarize the results of the DIANA-5 trial (randomized trial of a macro-Mediterranean diet for breast cancer recurrence) in context.
This study highlights the challenges in conducting large long term behavioral lifestyle interventions. The results showed no significant difference in breast cancer recurrence rates between the intervention and control groups (HR, 0.99; 95% CI, 0.69–1.14).
However, analysis by compliance showed that the highest tertile of Dietary Index change had reduced recurrence (HR 0.59; 95%CI 0.36–0.92) compared with those in the lowest tertile, which suggests that dietary changes may be beneficial if compliant.
The findings highlight the difficulties in conducting randomized behavioral dietary trials to ensure high adherence in the intervention group while maintaining baseline dietary habits in the control group for prolonged periods throughout the study duration.
Link to original study.”
Source: Urvi Shah/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023